New ABFO Member company open job posting - V P, Investor Relations & Corporate Communications

 

Vice President, Investor Relations and Corporate Communications

Position Overview

The Vice President, Investor Relations & Corporate Communications is an important, newly created position at Eiger.  Reporting to the CFO, this individual will be responsible for strategic and operational leadership of all IR and corporate communications activities.  This position will work with the senior leadership team to define and strengthen our IR plan, external communications strategy across multiple platforms, elevate Eiger’s external profile, and expand the company’s investor base.  The VP, Investor Relations & Corporate Communications will be responsible for external communications, including social media, press releases, corporate presentations, and investor call scripts.

Essential Duties and Responsibilities

  • Assess current investor relations plan and propose and drive new strategies and tactics to expand Eiger’s investor base and elevate Eiger’s external profile
  • Own external communications, including website, social media, corporate overview presentations, investor call materials (script, Q&A, messaging)
  • Conduct outreach to sell-side and buy-side analysts, investors, and media as needed
  • Build relationships with analysts, investors, and appropriate media contacts
  • Assess current investor base and identify new investors to target to convert to Eiger stockholders
  • Work with FP&A to manage/update consensus estimates and understand drivers of analysts’ financial models
  • Work with other functions internally to develop integrated communications plan, including scientific publications and KOL events
  • Track progress against IR and media plan; present updates to board as needed
  • Track and analyze competitive landscape across Eiger’s portfolio
  • Analyze impact of biopharmaceutical industry news and competitor news on Eiger’s operations and portfolio
  • Lead evaluation to identify IR and/or PR firms to provide additional support as needed
  • Manage participation and 1x1 meetings during investor/banking conferences
  • Work closely with CEO and senior leadership team and other internal functions to manage communications for ad hoc issues that are tailored to specific platforms/audiences but with clear, consistent underlying messages
  • Contribute to Eiger’s culture of compliance with IR function and across company, working with Legal, Finance, and Regulatory
  • Other responsibilities may be assigned

Position Requirements

  • Bachelor’s Degree required; MBA or higher scientific degree (e.g. MS, PhD) a plus
  • Relevant IR experience – 10+ years of experience in IR/Corporate Communications leadership position
  • Excellent communication skills; track-record of producing high-quality written content and presentations – applicants may be asked to submit portfolio of various written content or presentations
  • Ability to understand, assimilate, and communicate complex scientific and clinical information
  • Previous experience in rare disease or hepatology field a plus
  • Strong executive presence – able to communicate confidently and credibly with Eiger’s senior leadership team, board of directors, and external audiences including investors and media
  • Demonstrated expertise in communicating and building relationships with analysts and portfolio managers
  • Previous demonstrated ability to thrive in a fast-paced, small organization with multiple competing priorities and upcoming transformational milestones
  • Financial public relations and investment analysis experience, with an in-depth understanding of the dynamics of biopharmaceutical industry

About Eiger BioPharmaceuticals, Inc.

Eiger (NASDAQ:EIGR) is a publicly-traded, commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis. 

Eiger is developing two complementary treatments for HDV.  Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial.  Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.

Zokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies is the Company's first FDA approval.  A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA).  Outside the U.S., Eiger's established global Managed Access Program, expected to span greater than 40 countries, ensures all children and young adults with Progeria and Progeroid Laminopathies have access to treatment.

For additional information about Eiger, please visit www.eigerbio.com.

Association of Bioscience Financial Officers

If you are interested in this opportunity, please apply online HERE.

To view this html email as a web page in your browser, please use this link.

To see this and other open financial positions with our ABFO member companies,
please visit our ABFO website job posting page

THE ASSOCIATION OF BIOSCIENCE FINANCIAL OFFICERS - NORCAL CHAPTER
You are receiving this notice because you have indicated interest in ABFO, are an ABFO Member Representative,
or have come to one of our meetings.
If you have questions or comments or wish to be removed from our distribution list, please contact the ABFO Membership Coordinator, Genie Hawkins at abfogenie@comcast.net